[{"AccountsPayableCurrent_0_Q2_USD":4761000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":11000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":642000.0,"AssetsFairValueDisclosure_0_Q2_USD":169535000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":3028000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":59494000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":567000.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":2828000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":566000.0,"InvestmentIncomeInterest_2_Q2_USD":1937000.0,"InvestmentIncomeInterest_1_Q2_USD":801000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":340000.0,"OperatingLeaseExpense_2_Q2_USD":276000.0,"OperatingLeaseExpense_1_Q2_USD":138000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-64651000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-30550000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":160000.0,"NonoperatingIncomeExpense_2_Q2_USD":1937000.0,"NonoperatingIncomeExpense_1_Q2_USD":801000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":1118000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":168904000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-8923000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":169535000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-3203000.0,"ProceedsFromStockPlans_2_Q2_USD":324000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_2_Q2_USD":105147000.0,"PaymentsToAcquireShortTermInvestments_2_Q2_USD":43413000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":630000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":567000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1932000.0,"OperatingLeasePaymentsUse_2_Q2_USD":390000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":503000.0,"OperatingLeaseLiability_0_Q2_USD":3331000.0,"NumberOfOperatingSegments_2_Q2_segment":1.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":872000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":396000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":802000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":818000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":834000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q2_USD":851000.0,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":502000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":4203000.0,"LesseeOperatingLeaseDiscountRate_0_Q2_pure":0.1,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":228626000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":174000.0,"ShareBasedCompensation_2_Q2_USD":8503000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":21717000.0,"NetIncomeLoss_2_Q2_USD":-65281000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-65827000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":61734000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":890000.0,"LiabilitiesCurrent_0_Q2_USD":14904000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":243485000.0,"Liabilities_0_Q2_USD":17732000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":352000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.48,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.71,"CommonStockValue_0_Q2_USD":44000.0,"CommonStockSharesOutstanding_0_Q2_shares":44115612.0,"CommonStockSharesIssued_0_Q2_shares":44115612.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":59091000.0,"AssetsCurrent_0_Q2_USD":237819000.0,"Assets_0_Q2_USD":243485000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":4444344.0,"AdditionalPaidInCapital_0_Q2_USD":615691000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":630000.0,"NetIncomeLoss_1_Q2_USD":-31117000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":9193000.0,"ProfitLoss_2_Q2_USD":-65281000.0,"ProfitLoss_1_Q2_USD":-31117000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":8921000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":45501000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":22997000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"OperatingIncomeLoss_2_Q2_USD":-67218000.0,"OperatingIncomeLoss_1_Q2_USD":-31918000.0,"RestrictedCash_0_Q2_USD":403000.0,"OperatingExpenses_2_Q2_USD":67218000.0,"CommonStockSharesAuthorized_0_Q2_shares":120000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":9640000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":44074352.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":44098860.0,"StockholdersEquity_0_Q2_USD":225753000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-390612000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3331000.0,"OperatingExpenses_1_Q2_USD":31918000.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q2_USD":null,"Ticker":"RYTM","CIK":"1649904","name":"RHYTHM PHARMACEUTICALS, INC.","OfficialName":"Rhythm Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"415723429.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200803"}]